ClinicalTrials.gg
CompletedNCT02187861Updated Jun 5, 2019Results posted

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

A Phase 2 interventional study of Venetoclax and Bendamustine in Follicular Lymphoma, sponsored by Hoffmann-La Roche. Completed at 71 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing venetoclax in Lymphoma, Follicular — 1 open to participants now, 5 under way, none of them phase 3. venetoclax · Lymphoma, Follicular.

Enrollment
Largest of 14
163 · median 25
Started
2014
the only one that year
Phase 2
6 of 14
1 open now
Registered
1st of 14
by date
Lead sponsor
1 of 14
Hoffmann-La Roche

Among the 14 studies testing venetoclax in Lymphoma, Follicular, this one has the largest enrollment, is the only one that started in 2014, is one of 6 in phase 2, and was the 1st registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

1 of the 14 studies testing venetoclax in Lymphoma, Follicular is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing venetoclax in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This open-label, international, multicenter study will investigate the safety and efficacy of venetoclax (GDC-0199) in combination with bendamustine plus rituximab (venetoclax + BR) compared with BR alone in participants with relapsed and refractory fNHL, comparing two chemotherapy-containing regimens (Chemotherapy-Containing Cohort). In addition, an exploratory analysis of the safety and efficacy of venetoclax in combination with rituximab (venetoclax + rituximab), a chemotherapy-free regimen, will be performed (Chemotherapy-Free Cohort). Assignment to the Chemotherapy-Containing or Chemotherapy-Free Cohort will be decided at the discretion of the Investigator, unless one of the cohorts is not open to enrollment; in which case, participants may be enrolled only to the open cohort. The first 6 participants enrolled in the Chemotherapy-Containing Cohort (or more if required) will comprise the Safety Run-In group for Treatment Arm B, dosing venetoclax at 600 milligrams (mg) in combination with BR. Once a dose has been chosen from the Safety Run-In Period, randomization to the two treatment arms of the Chemotherapy-Containing Cohort (Arms B and C) will begin.

03

Conditions studied

  • Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed follicular lymphoma (FL) of Grade 1, 2, or 3a
  • Participants must have received at least one prior therapy for FL
  • For participants potentially receiving chemotherapy: if the participant has received prior bendamustine, response duration must have been greater than (>) 1 year
  • At least one bi-dimensionally on imaging scan defined as >1.5 centimeters (cm) in its longest dimension
  • (ECOG) Performance Status of 0, 1, or 2
  • Adequate hematologic function
  • For female participants of and male participants with female partners of childbearing potential, agreement to use one highly effective form of non-hormonal or two effective forms of non-hormonal contraception throughout the course of study treatment and for at least 30 days after the last dose of venetoclax and 12 months after the last dose of rituximab, whichever is longer
  • Confirmed availability of archival or freshly biopsied tumor tissue meeting protocol-defined specifications prior to study enrollment

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • to potential treatment agents
  • Ongoing use >30 milligrams per day (mg/day) of prednisone or equivalent. Participants receiving corticosteroid treatment with less than equal to (\</=) 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks duration prior to randomization (Cycle 1 Day 1)
  • Primary central nervous system (CNS) lymphoma
  • Vaccination with within 28 days prior to treatment
  • Chemotherapy or other therapy within five half-lives of a biologic agent with a minimum of 28 days prior to the start of Cycle 1
  • History of other that could affect compliance with the protocol or interpretation of results
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the participant
  • Significant cardiovascular disease (such as Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1
  • Requires the use of warfarin
  • history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Presence of positive test results for surface antigen or virus (HCV) antibody
  • Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
  • Participants with occult or prior hepatitis B virus (HBV) infection may be included if HBV deoxyribonucleic acid (DNA) is undetectable at screening. These participants must be willing to undergo monthly HBV DNA test until at least 12 months after the last treatment cycle
  • Known infection with (HIV) or human T-cell leukemia virus 1 (HTLV-1)
  • Pregnant or lactating
  • Recent major surgery (within 6 weeks before the start of Cycle 1 Day 1), other than for diagnosis
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)

    Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.

    Drug: Venetoclax · Drug: Bendamustine · Drug: Rituximab

  • Experimental
    Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)

    Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.

    Drug: Venetoclax · Drug: Rituximab

  • Experimental
    Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)

    Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.

    Drug: Venetoclax · Drug: Bendamustine · Drug: Rituximab

  • Active comparator
    Chemotherapy-Containing Cohort: Arm C (BR)

    Participants will receive rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.

    Drug: Bendamustine · Drug: Rituximab

Interventions

  • Venetoclax will be administered as per the schedule specified under arm description.

    Also known as: GDC-0199, ABT-199

  • Bendamustine will be administered as per the schedule specified under arm description.

    Also known as: Levact

  • Rituximab will be administered as per the schedule specified under arm description.

    Also known as: MabThera, Rituxan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)

    CMR: a score 1 (no uptake above background), 2 (uptake less than or equal to \[\<=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \<=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites with no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 6-8 weeks after Cycle 6 Day 1 (PRA) (Cycle length = 28 days)

Secondary outcomes

  1. Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA

    CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 4-10 weeks after Cycle 6 Day 1 (Cycle length = 28 days)

  2. Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1

    CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (uptake \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  3. Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1

    CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  4. Percentage of Participants With Complete Response (CR) According to IRC as Per Lugano Classification, Using Computed Tomography (CT) Scan

    CR: defined as reduction of longest transverse diameter of lesion (LDi) of target nodes/nodal masses to \<=1.5 centimeters (cm), and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  5. Percentage of Participants With CR According to Investigator as Per Lugano Classification, Using CT Scan

    CR: defined as reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  6. Percentage of Participants With Objective Response (OR) According to IRC as Per Lugano Classification, Using PET Scan

    OR was defined as CMR or Partial Metabolic Response (PMR). CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  7. Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET Scan

    OR was defined as CMR or PMR. CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  8. Percentage of Participants With OR According to IRC as Per Lugano Classification, Using CT Scan

    OR was defined as CR or Partial Response (PR). CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: greater than or equal to (\>=) 50 percent (%) decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  9. Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using CT Scan

    OR was defined as CR or PR. CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: \>=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

    Time frame: 4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)

  10. Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan

    OR was defined as CMR/CR or PMR/PR. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing).

    Time frame: Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)

  11. Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan

    DOR was defined as time from CMR/CR or PMR/PR until progressive disease (PD) or death due to any cause. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing). DOR was calculated using Kaplan-Meier method.

    Time frame: From CMR or PMR until disease progression or death due to any cause (assessed up to approximately 2.5 years)

  12. Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death

    PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.

    Time frame: Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)

  13. Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan

    PFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) until the date of disease progression, or death due to any cause. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. PFS was calculated using Kaplan-Meier method.

    Time frame: Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)

  14. Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy

    PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.

    Time frame: Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)

  15. Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan

    EFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to the date of disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. EFS was calculated using Kaplan-Meier method.

    Time frame: Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)

  16. Percentage of Participants Who Died Due to Any Cause

    Time frame: Baseline until death due to any cause (assessed up to approximately 2.5 years

  17. Overall Survival (OS)

    OS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to death due to any cause. For participants who are alive, OS was censored at the last contact. OS was calculated using Kaplan-Meier method.

    Time frame: Baseline until death due to any cause (assessed up to approximately 2.5 years)

  18. Apparent Clearance (CL) of Venetoclax

    CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

  19. Apparent Volume of Distribution (Vd) of Venetoclax

    Vd was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

  20. Time to Maximum Plasma Concentration (Tmax) of Venetoclax

    Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

  21. Maximum Plasma Concentration (Cmax) of Venetoclax

    Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

  22. Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax

    Area under the plasma concentration versus time curve from zero to the last measured concentration (AUClast).

    Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

  23. Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax

    Area under the plasma concentration versus time curve from time 0 (pre-dose) to 8 hours post dose (AUC0-8h).

    Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

07

Results

Posted Oct 13, 2017

Participant flow

Participant flow — Overall Study
MilestoneChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Started9525151
Treated9524950
Completed341919
Not completed6483232
Withdrew: Adverse event2121
Withdrew: Death0312
Withdrew: Physician decision0103
Withdrew: Progressive disease4421922
Withdrew: Withdrawal by subject0033
Withdrew: Other0171

Outcome measures

PrimaryPercentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)

CMR: a score 1 (no uptake above background), 2 (uptake less than or equal to \[\<=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \<=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites with no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
6-8 weeks after Cycle 6 Day 1 (PRA) (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)55.6 (21.20 to 86.30)11.5 (4.35 to 23.44)74.5 (60.37 to 85.67)70.6 (56.17 to 82.51)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: 3.92 · 95% CI -13.38 to 21.23
SecondaryPercentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA

CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
4-10 weeks after Cycle 6 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA55.6 (21.20 to 86.30)15.4 (6.88 to 28.08)70.6 (56.17 to 82.51)68.6 (54.11 to 80.89)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: 1.96 · 95% CI -15.89 to 19.81
SecondaryPercentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1

CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (uptake \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 155.6 (21.20 to 86.30)21.2 (11.06 to 34.70)41.2 (27.58 to 55.83)39.2 (25.84 to 53.89)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: 1.96 · 95% CI -17.07 to 20.99
SecondaryPercentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1

CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 155.6 (21.20 to 86.30)17.3 (8.23 to 30.33)39.2 (25.84 to 53.89)47.1 (32.93 to 61.54)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: -7.84 · 95% CI -27.01 to 11.32
SecondaryPercentage of Participants With Complete Response (CR) According to IRC as Per Lugano Classification, Using Computed Tomography (CT) Scan

CR: defined as reduction of longest transverse diameter of lesion (LDi) of target nodes/nodal masses to \<=1.5 centimeters (cm), and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) According to IRC as Per Lugano Classification, Using Computed Tomography (CT) Scan
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
6-8 weeks after Cycle 6 Day 144.4 (13.70 to 78.80)5.7 (1.18 to 15.66)39.2 (25.84 to 53.89)25.5 (14.33 to 39.63)
Year 155.6 (21.20 to 86.30)13.2 (5.48 to 25.34)27.5 (15.89 to 41.74)23.5 (12.79 to 37.49)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: 13.73 · 95% CI -4.24 to 31.69
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: 3.92 · 95% CI -12.98 to 20.82
SecondaryPercentage of Participants With CR According to Investigator as Per Lugano Classification, Using CT Scan

CR: defined as reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CR According to Investigator as Per Lugano Classification, Using CT Scan
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
4-10 weeks after Cycle 6 Day 122.2 (2.81 to 60.01)5.7 (1.18 to 15.66)15.7 (7.02 to 28.59)31.4 (19.11 to 45.89)
Year 133.3 (7.49 to 70.07)5.7 (1.18 to 15.66)13.7 (5.70 to 26.26)21.6 (11.29 to 35.32)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: -15.69 · 95% CI -31.87 to 0.49
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Difference in response rates: -7.84 · 95% CI -22.56 to 6.87
SecondaryPercentage of Participants With Objective Response (OR) According to IRC as Per Lugano Classification, Using PET Scan

OR was defined as CMR or Partial Metabolic Response (PMR). CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR) According to IRC as Per Lugano Classification, Using PET Scan
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
6-8 weeks after Cycle 6 Day 155.6 (21.20 to 86.30)21.2 (11.06 to 34.70)76.5 (62.51 to 87.21)74.5 (60.37 to 85.67)
Year 166.7 (29.93 to 92.51)32.7 (20.33 to 47.11)45.1 (31.13 to 59.66)51.0 (36.60 to 65.25)
SecondaryPercentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET Scan

OR was defined as CMR or PMR. CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET Scan
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
4-10 weeks after Cycle 6 Day 155.6 (21.20 to 86.30)28.8 (17.13 to 43.08)76.5 (62.51 to 87.21)76.5 (62.51 to 87.21)
Year 155.6 (21.20 to 86.30)21.2 (11.06 to 34.70)39.2 (25.84 to 53.89)49.0 (34.75 to 63.40)
SecondaryPercentage of Participants With OR According to IRC as Per Lugano Classification, Using CT Scan

OR was defined as CR or Partial Response (PR). CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: greater than or equal to (\>=) 50 percent (%) decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With OR According to IRC as Per Lugano Classification, Using CT Scan
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
6-8 weeks after Cycle 6 Day 166.7 (29.93 to 92.51)30.2 (18.34 to 44.34)80.4 (66.88 to 90.18)84.3 (71.41 to 92.98)
Year 166.7 (29.93 to 92.51)22.6 (12.28 to 36.21)41.2 (27.58 to 55.83)60.8 (46.11 to 74.16)
SecondaryPercentage of Participants With OR According to Investigator as Per Lugano Classification, Using CT Scan

OR was defined as CR or PR. CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: \>=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.

Time frame:
4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using CT Scan
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
4-10 weeks after Cycle 6 Day 155.6 (21.20 to 86.30)32.1 (19.92 to 46.32)74.5 (60.37 to 85.67)78.4 (64.68 to 88.71)
Year 155.6 (21.20 to 86.30)28.3 (16.79 to 42.35)47.1 (32.93 to 61.54)49.0 (34.75 to 63.40)
SecondaryPercentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan

OR was defined as CMR/CR or PMR/PR. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing).

Time frame:
Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan66.7 (29.93 to 92.51)36.5 (23.62 to 51.04)80.4 (66.88 to 90.18)80.4 (66.88 to 90.18)
SecondaryDuration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan

DOR was defined as time from CMR/CR or PMR/PR until progressive disease (PD) or death due to any cause. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing). DOR was calculated using Kaplan-Meier method.

Time frame:
From CMR or PMR until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Reported as:
Median · months
Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan
monthsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan32.46 (9.46 to 32.46)15.79 (10.15 to 23.49)24.87 (12.45 to NA)15.64 (12.09 to NA)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.69 · 95% CI 0.38 to 1.27HR was calculated using Cox regression.
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.78 · 95% CI 0.43 to 1.40HR was calculated using Cox regression.
SecondaryPercentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death

PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.

Time frame:
Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death44.486.541.252.9
SecondaryProgression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan

PFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) until the date of disease progression, or death due to any cause. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. PFS was calculated using Kaplan-Meier method.

Time frame:
Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Reported as:
Median · months
Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
monthsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan35.09 (12.78 to 35.09)6.57 (6.18 to 12.25)27.63 (16.07 to NA)18.43 (16.92 to NA)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.69 · 95% CI 0.38 to 1.24HR was calculated using Cox regression.
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.77 · 95% CI 0.43 to 1.36HR was calculated using Cox regression.
SecondaryPercentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy

PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.

Time frame:
Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy44.486.541.252.9
SecondaryEvent-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan

EFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to the date of disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. EFS was calculated using Kaplan-Meier method.

Time frame:
Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)
Reported as:
Median · months
Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
monthsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan35.09 (12.78 to 35.09)6.57 (6.18 to 12.25)27.63 (16.07 to NA)18.43 (16.92 to NA)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.69 · 95% CI 0.38 to 1.24HR was calculated using Cox regression.
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.77 · 95% CI 0.43 to 1.36HR was calculated using Cox regression.
SecondaryPercentage of Participants Who Died Due to Any Cause
Time frame:
Baseline until death due to any cause (assessed up to approximately 2.5 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Died Due to Any Cause
percentage of participantsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Percentage of Participants Who Died Due to Any Cause05.82.03.9
SecondaryOverall Survival (OS)

OS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to death due to any cause. For participants who are alive, OS was censored at the last contact. OS was calculated using Kaplan-Meier method.

Time frame:
Baseline until death due to any cause (assessed up to approximately 2.5 years)
Reported as:
Median · months
Overall Survival (OS)
monthsChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.48 · 95% CI 0.04 to 5.37HR was calculated using Cox regression.
  • Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) vs Chemotherapy-Containing Cohort: Arm C (BR) · Hazard ratio (hr): 0.51 · 95% CI 0.05 to 5.63HR was calculated using Cox regression.
SecondaryApparent Clearance (CL) of Venetoclax

CL is a quantitative measure of the rate at which a drug substance is removed from the body.

Time frame:
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

No measurements were reported for this outcome.

SecondaryApparent Volume of Distribution (Vd) of Venetoclax

Vd was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)

No measurements were reported for this outcome.

SecondaryTime to Maximum Plasma Concentration (Tmax) of Venetoclax
Time frame:
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Venetoclax
hoursChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)
Time to Maximum Plasma Concentration (Tmax) of Venetoclax8.00 (4.00 to 8.08)6.00 (1.95 to 8.18)6.21 (1.98 to 9.22)
SecondaryMaximum Plasma Concentration (Cmax) of Venetoclax
Time frame:
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Venetoclax
nanograms per milliliter (ng/mL)Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)
Maximum Plasma Concentration (Cmax) of Venetoclax1350 ± 4271220 ± 4781340 ± 460
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax

Area under the plasma concentration versus time curve from zero to the last measured concentration (AUClast).

Time frame:
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax
hours*ng/mLChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)
Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax5310 ± 17304950 ± 19505500 ± 2270
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax

Area under the plasma concentration versus time curve from time 0 (pre-dose) to 8 hours post dose (AUC0-8h).

Time frame:
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax
hours*ng/mLChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)
Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax5240 ± 18604820 ± 19805330 ± 2270

Adverse events

Collected over Baseline up to approximately 2.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)—4/9 (44.4%)9/9 (100%)
Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)—16/52 (30.8%)49/52 (94.2%)
Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)—26/49 (53.1%)49/49 (100%)
Chemotherapy-Containing Cohort: Arm C (BR)—12/50 (24%)48/50 (96%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
Febrile neutropeniaBlood and lymphatic system disorders1/90/526/493/50
ThrombocytopeniaBlood and lymphatic system disorders1/90/521/490/50
Cardiac failureCardiac disorders1/90/520/490/50
PyrexiaGeneral disorders1/90/520/490/50
Acute sinusitisInfections and infestations1/90/520/490/50
Clostridium difficile colitisInfections and infestations1/90/520/490/50
Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/90/523/490/50
SyncopeNervous system disorders1/90/521/491/50
NEUTROPENIABlood and lymphatic system disorders1/90/521/490/50
Pneumocystis jirovecii pneumoniaInfections and infestations0/90/523/490/50
Most frequent other events
Showing 10 of 104
Most frequent other events
EventChemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)
NauseaGastrointestinal disorders7/914/5232/4923/50
NeutropeniaBlood and lymphatic system disorders5/914/5230/4917/50
ThrombocytopeniaBlood and lymphatic system disorders3/97/5228/498/50
DiarrhoeaGastrointestinal disorders5/921/5224/4914/50
VomitingGastrointestinal disorders4/97/5223/4913/50
FatigueGeneral disorders3/913/5221/4915/50
AnaemiaBlood and lymphatic system disorders2/93/5219/498/50
Infusion related reactionInjury, poisoning and procedural complications2/918/5210/497/50
ConstipationGastrointestinal disorders3/95/5210/4917/50
NasopharyngitisInfections and infestations3/94/521/490/50

Baseline characteristics

Intent-to-treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)Total
Mean57.9 ± 12.761.9 ± 12.064.9 ± 9.861.0 ± 11.662.3 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)Chemotherapy-Containing Cohort: Arm C (BR)Total
Female525162167
Male427353096
08

Study locations

71 sites
  • Southern Cancer Center, PC
    Mobile, Alabama 36608, United States
  • Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • UCLA School of Medicine; Hematology/Oncology
    Los Angeles, California 90095, United States
  • Nothwest Georgia Oncology Centers P.C
    Austell, Georgia 30106, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Illinois at Chicago College of Medicine
    Chicago, Illinois 60612-7302, United States
  • Primary Healthcare Associates SC - Harvey
    Harvey, Illinois 60426, United States
  • University of Kansas; Medical Center & Medical pavilion
    Westwood, Kansas 66205, United States
  • Sidney Kimmel Comp Cancer Ctr
    Baltimore, Maryland 21231-1000, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • James P. Wilmot Cancer Center
    Rochester, New York 14642, United States
  • University of Pennsylvania; School of Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • VCU Massey Cancer Center
    Richmond, Virginia 23298-003, United States
  • West Virginia Uni Med. Center - Robert Byrd Health Science
    Morgantown, West Virginia 26506, United States
  • Royal Prince Alfred Hospital; Medical Oncology
    Camperdown, New South Wales 2050, Australia
  • St George Hospital
    Kogarah, New South Wales, New South Wales 2217, Australia
  • Royal North Shore Hospital
    St. Leonards, New South Wales 2065, Australia
  • Westmead Hospital; Haematology
    Sydney, New South Wales 2145, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Townsville General Hospital
    Douglas, Queensland 4184, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Queen Elizabeth Hospital; Haematology
    Woodville South, South Australia 5011, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • ZNA Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint Jan
    Brugge, 8000, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • British Columbia Cancer Agency
    Kelowna, British Columbia V1Y 5L3, Canada
  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept
    Toronto, Ontario M5G 2M9, Canada
  • Hopital Maisonneuve- Rosemont; Oncology
    Montreal, Quebec H1T 2M4, Canada
  • Chum Hopital Notre Dame; Centre D'Oncologie
    Montreal, Quebec H2L 4M1, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Saskatoon Cancer Centre; Uni of Saskatoon Campus
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Institut de Cancerologie de l'Ouest
    Angers, 49933, France
  • CHU Clermont Ferrand - Hôpital d'Estaing
    Clermont Ferrand cedex 1, 63003, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • CHU de Dijon - Hopital le Bocage
    Dijon, 21000, France
  • Centre Jean Bernard
    Le Mans, 72015, France
  • CHU Montpellier
    Montpellier, 34295, France
  • Centre Hospitalier Lyon Sud; Hematolgie
    Pierre Benite, 69495, France
  • Klinikum Chemnitz gGmbH; Klinik f. Innere Medizin III
    Chemnitz, 09116, Germany
  • Städtisches Klinikum Dessau
    Dessau-Roßlau, 06847, Germany
  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
    Dresden, 01307, Germany
  • Universitätsklinik Essen; Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
    Essen, 45122, Germany
  • Universitätsklinikum Jena; Klinik für Innere Medizin II
    Jena, 07747, Germany
  • Universitätsklinikum Köln; Klinik I für Innere Medizin
    Koeln, 50937, Germany
  • Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Med. Klinik I, Hämatologie/Onkologie
    Lübeck, 23562, Germany
  • Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik
    Mainz, 55131, Germany
  • Universitätsklinikum Ulm; Apotheke
    Ulm, 89075, Germany
  • Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Hämatologie / Onkologie
    Würzburg, 97080, Germany
  • A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
    Bologna, Emilia-Romagna 40138, Italy
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
    Meldola, Emilia-Romagna 47014, Italy
  • Ospedale di Ravenna
    Ravenna, Emilia-Romagna 48100, Italy
  • Ospedale Infermi di Rimini
    Rimini, Emilia-Romagna 47900, Italy
  • Asst Papa Giovanni XXIII
    Bergamo, Lombardia 24100, Italy
  • Ospedale Niguarda Milano
    Milano, Lombardia 20162, Italy
  • Irccs Policlinico San Matteo; Divisione Di Ematologia
    Pavia, Lombardia 27100, Italy
  • Azienda Ospedale San Giovanni
    Torino, Piemonte 10126, Italy
  • Az. Osp. Di Careggi; Divisione Di Ematologia
    Firenze, Toscana 50135, Italy
  • Blackpool Victoria Hospital
    Blackpool, FY3 8NR, United Kingdom
  • St James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Leicester Royal Infirmary; Dept. of Medical Oncology
    Leicester, LE1 5WW, United Kingdom
  • University College London, Department of Haematology
    London, NW1 2PG, United Kingdom
  • Royal Marsden Nhs Trust; Consultant Cancer Physician
    London, SW3 6JJ, United Kingdom
  • Christie Hospital; Breast Cancer Research Office
    Manchester, M20 4QL, United Kingdom
  • Churchill Hospital; Oxford Cancer and Haematology Centre
    Oxford, OX3 7LJ, United Kingdom
  • Royal Marsden NHS Foundation Trust
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, Le Du K, Arthur C, Pro B, Gritti G, Crump M, Petrich A, Samineni D, Sinha A, Punnoose EA, Szafer-Glusman E, Spielewoy N, Mobasher M, Humphrey K, Kornacker M, Hiddemann W. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020 Dec 3;136(23):2628-2637. doi: 10.1182/blood.2020005588. PubMed 32785666 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Sep 2016, 21 months.

Results were first posted in Oct 2017, 1 year after primary completion.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 21 months is below that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2014
First posted
Jul 11, 2014
StartActual
Dec 1, 2014
Primary completionActual
Sep 27, 2016
CompletionActual
Mar 16, 2018
Results first posted
Oct 13, 2017
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02187861
Lead sponsor
Hoffmann-La Roche
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Jul 11, 2014
Start date
Dec 1, 2014
Primary completion
Sep 27, 2016
Completion
Mar 16, 2018
Results posted
Oct 13, 2017
Last update
Jun 5, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Bendamustine

Start the discussion